On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
Reversing opioid overdoses in rats using a drug that does not enter the brain prevents the sudden and severe withdrawal symptoms associated with therapeutics that target the central nervous system.
New research found that individuals with anorexia nervosa have elevated opioid neurotransmitter activity, which may ...
A study conducted at Turku PET Center in Finland showed that changes in the functioning of opioid neurotransmitters in the ...
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous ...
The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...
NEW HAVEN, Conn., Jan. 30, 2025 /PRNewswire/ -- (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the ...
Mu-opioid receptor (MOR) functions as a part of complex opioid system and supports both homeostatic and hedonic control of eating behavior. All subjects underwent a screening visit consisting of ...